These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38468289)

  • 1. Genetically engineered membrane-based nanoengagers for immunotherapy of pancreatic cancer.
    Zhang H; Li Y; Kang H; Lan J; Hou L; Chen Z; Li F; Liu Y; Zhao J; Li N; Wan Y; Zhu Y; Zhao Z; Zhang H; Zhuang J; Huang X
    J Nanobiotechnology; 2024 Mar; 22(1):104. PubMed ID: 38468289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Cell Nanovaccines Based on Genetically Engineered Antibody-Anchored Membrane.
    Li Y; Zhang H; Wang R; Wang Y; Li R; Zhu M; Zhang X; Zhao Z; Wan Y; Zhuang J; Zhang H; Huang X
    Adv Mater; 2023 Mar; 35(13):e2208923. PubMed ID: 36715052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.
    Gao J; Wang Z; Jiang W; Zhang Y; Meng Z; Niu Y; Sheng Z; Chen C; Liu X; Chen X; Liu C; Jia K; Zhang C; Liao H; Jung J; Sung E; Chung H; Zhang JZ; Zhu AX; Shen L
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.
    Qi J; Li X; Peng H; Cook EM; Dadashian EL; Wiestner A; Park H; Rader C
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):E5467-E5476. PubMed ID: 29844189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD40 immunotherapy for pancreatic cancer.
    Vonderheide RH; Bajor DL; Winograd R; Evans RA; Bayne LJ; Beatty GL
    Cancer Immunol Immunother; 2013 May; 62(5):949-54. PubMed ID: 23589109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.
    Rossi DL; Rossi EA; Cardillo TM; Goldenberg DM; Chang CH
    MAbs; 2014; 6(2):381-91. PubMed ID: 24492297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
    Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
    J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bispecific antibodies: An old story with a bright future… with CAR-T cells!].
    Riffard C; Teillaud JL
    Bull Cancer; 2021 Oct; 108(10S):S168-S180. PubMed ID: 34920800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma.
    Gardell JL; Matsumoto LR; Chinn H; DeGolier KR; Kreuser SA; Prieskorn B; Balcaitis S; Davis A; Ellenbogen RG; Crane CA
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33122397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activating Macrophage-Mediated Cancer Immunotherapy by Genetically Edited Nanoparticles.
    Rao L; Zhao SK; Wen C; Tian R; Lin L; Cai B; Sun Y; Kang F; Yang Z; He L; Mu J; Meng QF; Yao G; Xie N; Chen X
    Adv Mater; 2020 Nov; 32(47):e2004853. PubMed ID: 33089578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy.
    Au KM; Park SI; Wang AZ
    Sci Adv; 2020 Jul; 6(27):eaba8564. PubMed ID: 32923587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma.
    Stromnes IM; Burrack AL; Hulbert A; Bonson P; Black C; Brockenbrough JS; Raynor JF; Spartz EJ; Pierce RH; Greenberg PD; Hingorani SR
    Cancer Immunol Res; 2019 Jun; 7(6):977-989. PubMed ID: 31028033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells.
    Asano R; Watanabe Y; Kawaguchi H; Fukazawa H; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Biol Chem; 2007 Sep; 282(38):27659-65. PubMed ID: 17644522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.
    Satta A; Mezzanzanica D; Caroli F; Frigerio B; Di Nicola M; Kontermann RE; Iacovelli F; Desideri A; Anichini A; Canevari S; Gianni AM; Figini M
    MAbs; 2018 Oct; 10(7):1084-1097. PubMed ID: 29993310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.
    Zhu G; Foletti D; Liu X; Ding S; Melton Witt J; Hasa-Moreno A; Rickert M; Holz C; Aschenbrenner L; Yang AH; Kraynov E; Evering W; Obert L; Lee C; Sai T; Mistry T; Lindquist KC; Van Blarcom T; Strop P; Chaparro-Riggers J; Liu SH
    Sci Rep; 2019 Jun; 9(1):8420. PubMed ID: 31182754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy.
    Byrne KT; Leisenring NH; Bajor DL; Vonderheide RH
    J Immunol; 2016 Jul; 197(1):179-87. PubMed ID: 27217585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of polymerized liposomal nanoparticles.
    Girgis MD; Federman N; Rochefort MM; McCabe KE; Wu AM; Nagy JO; Denny C; Tomlinson JS
    J Surg Res; 2013 Nov; 185(1):45-55. PubMed ID: 23827791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer
    Chen J; Guo XZ; Li HY; Zhao JJ; Xu WD
    World J Gastroenterol; 2017 Feb; 23(5):817-829. PubMed ID: 28223726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.
    Gedeon PC; Schaller TH; Chitneni SK; Choi BD; Kuan CT; Suryadevara CM; Snyder DJ; Schmittling RJ; Szafranski SE; Cui X; Healy PN; Herndon JE; McLendon RE; Keir ST; Archer GE; Reap EA; Sanchez-Perez L; Bigner DD; Sampson JH
    Clin Cancer Res; 2018 Aug; 24(15):3611-3631. PubMed ID: 29703821
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.